AmerisourceBergen to Launch Digital Therapeutics Platform to Facilitate Access to Innovative Products

Conshohocken, Pennsylvanie, États-Unis (27 juillet) – Alors que le pipeline de thérapies numériques (DTx) continue de se développer, AmerisourceBergen a annoncé aujourd’hui son intention de lancer DTx Connect, une plateforme de commande, de distribution et d’exécution entièrement intégrée qui vise à faciliter l’accès des patients aux thérapies et diagnostics numériques prescrits par les médecins. La plateforme, qui s’intègre de manière transparente aux dossiers médicaux électroniques (DME), permet aux médecins d’accéder facilement aux DTx sur ordonnance et en vente libre et de les commander par le biais de leur flux de travail d’ordonnance électronique, puis de surveiller l’exécution des patients.

Catégorie en pleine croissance dans le domaine de la santé numérique, DTx fournit des interventions cliniques directement aux patients via un logiciel pour traiter, gérer ou prévenir un large éventail de maladies et de troubles, y compris les problèmes de santé comportementale et le diabète. Les produits, qui nécessitent parfois une ordonnance, peuvent être utilisés comme thérapies autonomes ou en combinaison avec d’autres traitements ou dispositifs. Les thérapies numériques diffèrent des autres outils de santé numériques, en partie parce qu’elles doivent être autorisées ou certifiées par des organismes de réglementation pour étayer les allégations de risque, d’efficacité et d’utilisation prévue. Le marché devrait croître à un taux de croissance annuel composé de près de 25 % de 2022 à 2030 aux États-Unis.

Plusieurs entreprises de santé numérique prévoient de piloter la plateforme, notamment Mahana Therapeutics, l’un des principaux développeurs de thérapies numériques sur ordonnance conçues pour autonomiser les patients atteints de maladies chroniques, et Videra Health, une plateforme d’évaluation vidéo assistée par l’IA et de surveillance à distance des patients.

“While digital therapeutics and diagnostics offer tremendous potential, addressing challenges across the provider workstream and patient journey remain critical to unlocking the value these products have to offer,” said Jason Dinger, SVP of Strategy and Innovation at AmerisourceBergen. “Given our role in the supply chain and our portfolio of commercialization services, we are uniquely positioned to build a solution that aims to address unmet needs and helps patients start and stay on physician-ordered products. DTx Connect, in addition to AmerisourceBergen’s patient support and market access consulting services, enables us to deliver enhanced support across the product lifecycle, helping to advance accessibility.”

DTx Connect, which is EMR- and brand-agnostic, provides a real-time, secure digital connection between developers and physicians via the EMR. The platform is powered through a collaboration with patient engagement technology company Twistle. Key features include:

• E-prescribing through EMR: Physicians can search for digital therapeutics and diagnostic tools via a digital catalog and then order the products within their e-prescribing workflow.
• Efficient dispense and fulfillment: After a physician orders a product, DTx Connect delivers a welcome message on behalf of the care team via text or within the patient portal. Patients also receive an electronic link which enables them to download the prescription or non-prescription product and access educational materials.
• Patient support services: Patient services—delivered via text, a digital companion app, and phone calls with clinical teams—aim to simplify the adoption and onboarding process, keep patients engaged throughout the treatment journey and monitor and manage adherence.
• Patient Status Alerts: DTx Connect provides physicians with patient status alerts, including notifications for patient fulfillment. The increased visibility throughout the patient journey enables physicians to make more informed engagement and care plan decisions in support of the prescribed therapy regimen.

“AmerisourceBergen has spent decades ensuring that patients have timely access to healthcare products. Their experience will bring a unique perspective to our community, particularly as they launch DTx Connect," said Andy Molnar, CEO of the Digital Therapeutics Alliance (DTA), a global nonprofit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics. AmerisourceBergen is a member of DTA. “Getting digital therapeutics into the hands of more people who need them is a primary focus of DTA's global efforts and platforms like DTx Connect will help advance accessibility of high quality, evidence-based DTx products."

The launch of DTx Connect bolsters the support AmerisourceBergen offers to DTx developers throughout the commercialization journey. In addition to the capabilities available through DTx Connect, AmerisourceBergen can deliver services to support DTx developers’ strategic planning and launch activities, including market access consulting, real-world evidence planning and engaging healthcare decision makers via AB’s FormularyDecisions platform. For more information on DTx Connect, please visit: https://www.amerisourcebergen.com/manufacturer-solutions/digital-therapeutics

###

About AmerisourceBergen

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 42,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at www.amerisourcebergen.com.